AskBio gene therapy shows safety signals at 52 weeks
Patients treated with AskBio’s limb‑girdle muscular dystrophy candidate AB‑1003 had no serious adverse events through as much as 52 weeks, with mostly mild-to-moderate events like headaches, falls and nausea reported. The sponsor presented these safety data as part of ongoing follow-up for the program (cgtlive.com). Longer-term safety readouts matter in dosing and release strategies, and these topline results reduce one uncertainty for manufacturing and clinical planning (cgtlive.com).
Gene therapy is a one-time attempt to deliver a working copy of a broken gene, like mailing a clean instruction manual into cells that have been using a damaged one. AskBio’s AB-1003 is built to do that for a rare muscle-wasting disease called limb-girdle muscular dystrophy type 2I/R9. (clinicaltrials.gov) That disease is tied to changes in a gene called FKRP, which helps muscle cells maintain the protein scaffolding around them. When FKRP is faulty, muscles in the hips and shoulders gradually weaken, and some patients also develop breathing or heart problems. (nih.gov) AB-1003 uses an adeno-associated virus, which is a stripped-down delivery shell often used in gene therapy because it can carry genetic cargo into cells. In this trial, patients get a single intravenous infusion, so the treatment is sent through the bloodstream rather than injected muscle by muscle. (clinicaltrials.gov) The first thing researchers watch after a gene therapy infusion is safety, because the body can react to both the viral shell and the new gene cargo. AskBio said the first five participants in the first cohort had no dose-limiting toxicities and no serious adverse events through as much as 52 weeks after treatment. (askbio.com) The side effects reported so far were mostly mild to moderate, including headache, nausea, vomiting, fever, fatigue, and falls. The company presented those interim results at the 30th Annual International Congress of the World Muscle Society in Vienna in October 2025. (bayer.com) This is an early-stage study, so the numbers are still small and the first cohort was blinded, meaning some participants received placebo instead of the gene therapy. The trial is randomized and placebo-controlled, and participants in Part 1 are being treated in sequential dose-level cohorts to see what dose looks tolerable before moving further. (clinicaltrials.gov) The safety readout was strong enough for the independent Data Safety Monitoring Board to recommend moving to the second cohort. AskBio then announced on March 7, 2025, that the first participant in that second cohort had been dosed. (askbio.com) The company is also watching patients long after the first year, because gene therapy risks can show up late and regulators usually want extended follow-up. In LION-CS101, participants complete the main 52-week trial period and then enter a planned four-year long-term follow-up period. (askbio.com) That longer clock matters because muscle gene therapies have had a rough history with immune reactions, liver signals, and dose questions across the field. A clean first-year safety picture does not prove the treatment works, but it does clear one of the biggest early hurdles for a program trying to move from a tiny first cohort into broader testing. (fda.gov; clinicaltrials.gov) As of the latest ClinicalTrials.gov update posted February 20, 2026, the study was still listed as recruiting. That means the story here is not a finish line but a checkpoint: five first-cohort patients, up to 52 weeks of follow-up, no serious adverse events reported so far, and a second cohort already underway. (clinicaltrials.gov)
